Protocol Ledger

NCT05253209 · Phase III · TERMINATED

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart D

Interventional Phase III clinical trial protocol NCT05253209 sponsored by Asklepion Pharmaceuticals in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-29 Enrollment: 64 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05253209
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)64 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05253209
Protocol FieldVerified Registry Value
NCT IdentifierNCT05253209
Consolidated Lead SponsorAsklepion Pharmaceuticals
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment64 participants (ACTUAL)
Registered Start Date2022-06-29
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05253209
Hospital Research SiteLocationSite Profile
Northwestern Memorial and Lurie Cancer CenterChicago, ILOpen Hospital Dossier ->
Duke University Medical CenterDurham, NCOpen Hospital Dossier ->
Cincinnati Children's Hospital Medical CenterCincinnati, OHOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI